A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer. (Q36671270)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

20 December 2019

main subject

phase II clinical trial

0 references

0 references

author

Srinivasan Madhusudan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Helena Earl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Fran Balkwill

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Adrian Harris

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

A Protheroe

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

D Propper

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

C Han

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

P Corrie

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

B Hancock

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

P Vasey

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

A Turner

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

S Hoare

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

language of work or name

English

0 references

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

1418-1422

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601321

20 December 2019

exact match

0 references

cites work

Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Therapeutic options in the management of renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Phase II evaluation of bryostatin-1 in metastatic melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

A phase II study of bryostatin 1 in metastatic malignant melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Phase Ib trial of bryostatin 1 in patients with refractory malignancies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Varied differentiation responses of human leukemias to bryostatin 1.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Successful treatment of murine melanoma with bryostatin 1.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Bryostatin 1 activates T cells that have antitumor activity.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Global increases in kidney cancer incidence, 1973-1992.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

20 September 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

Redistribution and enhanced protein kinase C-mediated phosphorylation of alpha- and gamma-adducin during renal tumor progression

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394342

The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients

20 September 2018

1 reference

12 December 2020

Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study

1 reference

12 December 2020

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer

1 reference

12 December 2020

Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients

1 reference

12 December 2020

Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study

1 reference

12 December 2020

Co-induction of lymphokine synthesis by the antineoplastic bryostatins

1 reference

12 December 2020

The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells

1 reference

12 December 2020

The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601321

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14562010%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference